Glioblastoma Multiforme
📧 Sign up to get email alerts when something new happens for Glioblastoma Multiforme.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine [Phase 2]
Phase 2 clinical trial evaluating TTFields with radiosurgery for recurrent glioblastoma, with auxiliary imaging using 18F-Fluoro-Ethyl-Thyro…
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme [Phase 2]
Phase 2 clinical trial evaluating dalteparin in combination with radiation therapy for newly diagnosed supratentorial glioblastoma multiform…
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme [Phase 2]
Phase 2 clinical trial evaluating high-dose methotrexate with leucovorin in newly diagnosed glioblastoma multiforme (brain and CNS tumors).
-
CLINICAL_TRIALS trial_result · 2023-06-01Clinical Trial Update: Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma [Phase 1, Phase 2]
A Phase I/II trial evaluating TVI-Brain-1 for safety and efficacy in recurrent high-grade gliomas, including glioblastoma multiforme, has co…
-
CLINICAL_TRIALS trial_result · 2023-04-14Clinical Trial Update: 131I-IPA and Concurrent XRT in Recurrent GBM [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluating 131I-IPA with concurrent radiotherapy in recurrent glioblastoma multiforme.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma [Phase 1]
Phase 1 trial update of neural stem cell–based virotherapy for newly diagnosed malignant glioma; study completed with results posted in 2023…
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: Evaluation of GLR2007 for Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating GLR2007 for advanced solid tumors has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-21Clinical Trial Update: Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. [Phase 1, Phase 2]
Clinical trial update for Parvovirus H-1 (ParvOryx) in progressive primary or recurrent glioblastoma multiforme completed Phase 1/2.
-
CLINICAL_TRIALS trial_result · 2022-08-15Clinical Trial Update: Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children [Phase 2]
Phase 2 pilot study of cabozantinib for recurrent or progressive central nervous system tumors in children has been terminated; results were…
-
FDA approval · 2022-08-03FDA Approved: TEMOZOLOMIDE — Supplemental Application (Accord Healthcare Inc.)
FDA approves a supplemental application for Temozolomide from Accord Healthcare Inc., a generic cancer drug.
-
CLINICAL_TRIALS trial_result · 2022-06-23Clinical Trial Update: TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma [Phase 2]
Phase 2 trial update on TTFields combined with pulsed bevacizumab for recurrent glioblastoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2022-05-18Clinical Trial Update: Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer [Phase 3]
A Phase 3 clinical trial update for DCVax-L in newly diagnosed glioblastoma multiforme is reported with unknown current status.
-
CLINICAL_TRIALS trial_result · 2022-02-24Clinical Trial Update: BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma [Phase 1, Phase 2]
Phase 1/2 trial of Onivyde with metronomic temozolomide in recurrent glioblastoma has been terminated; results posted prior to termination.
-
CLINICAL_TRIALS trial_result · 2022-02-01Clinical Trial Update: DC Migration Study for Newly-Diagnosed GBM [Phase 2]
Phase 2 clinical trial update on dendritic cell migration for newly diagnosed glioblastoma; study completed with results posted in 2022.
-
FDA approval · 2021-11-23FDA Approved: TEMOZOLOMIDE — Original Application (Nivagen Pharmaceuticals, Inc.)
FDA approved temozolomide from Nivagen Pharmaceuticals under an original application for the treatment of malignant gliomas, including gliob…
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme [Phase 1, Phase 2]
A clinical trial evaluating safety and efficacy of ACT001 in combination with anti-PD-1 in patients with surgically accessible recurrent gli…
-
CLINICAL_TRIALS trial_result · 2021-11-09Clinical Trial Update: Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens [Phase 1]
Phase 1 trial evaluating peptide targets for glioblastoma against novel cytomegalovirus antigens; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-10-18Clinical Trial Update: Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme [Phase 2]
Phase 2 trial evaluating temozolomide alone or in combination with thalidomide, isotretinoin, and/or celecoxib in glioblastoma multiforme pa…
-
CLINICAL_TRIALS trial_result · 2021-08-25Clinical Trial Update: Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) [Phase 1, Phase 2]
Phase I/II trial of vorinostat, erlotinib, and temozolomide in recurrent glioblastoma multiforme (GBM) was terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-23Clinical Trial Update: Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) [Phase 1, Phase 2]
Phase 1/2 trial of USL311 +/- lomustine in advanced solid tumors and relapsed/recurrent glioblastoma multiforme (GBM) was terminated with re…
-
CLINICAL_TRIALS trial_result · 2021-07-21Clinical Trial Update: Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma [Phase 2]
Phase 2 trial evaluating valproic acid with radiation and bevacizumab in pediatric high-grade gliomas and diffuse intrinsic pontine glioma h…
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) [Phase 2]
A Phase 2 clinical trial update for MBM-02 (Tempol) investigating treatment for glioblastoma/ glioblastoma multiforme is listed as status UN…
-
FDA approval · 2021-04-30FDA Approved: CARMUSTINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for Carmustine submitted by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. This actio…
-
CLINICAL_TRIALS trial_result · 2021-04-19Clinical Trial Update: A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme [Phase 2, Phase 3]
Phase II/III study evaluating high-dose, intermittent sunitinib for recurrent glioblastoma multiforme is ongoing with unknown status.
-
CLINICAL_TRIALS trial_result · 2021-04-14Clinical Trial Update: UNITE Study: Understanding New Interventions With GBM ThErapy [Phase 3]
Phase 3 UNITE trial in glioblastoma multiforme was terminated with results posted.